Nutriband Inc NTRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.52
- Day Range
- $3.35–3.52
- 52-Week Range
- $3.21–11.68
- Bid/Ask
- $2.80 / $3.50
- Shares Outstanding
- 12.16M
- Market Cap
- $41.21M
- Volume/Avg
- 6,289 / 10,270
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 23.23
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.nutriband.com
Valuation
|
Metric
|
NTRB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.15 |
Price/Sales | 23.23 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
NTRB
|
|---|---|
Quick Ratio | 4.82 |
Current Ratio | 5.26 |
Interest Coverage | −370.70 |
Quick Ratio
NTRB
Profitability
|
Metric
|
NTRB
|
|---|---|
Return on Assets (Normalized) | −61.95% |
Return on Equity (Normalized) | −71.82% |
Return on Invested Capital (Normalized) | −68.41% |
Return on Assets
NTRB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Pzjmqbw | Mjxjfy | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xpttplmd | Dqbhs | $64B | |||
| argenx SE ADR
ARGX
| Swthjvhqk | Pzmf | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mdfvlvp | Xrndxlf | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Zxpzrpqswd | Fmwly | $24B | |||
| BioNTech SE ADR
BNTX
| Vvcsvmsm | Zttp | $23B | |||
| Incyte Corp
INCY
| Jcbpvzvz | Zsns | $22B | |||
| Moderna Inc
MRNA
| Xqpdmgyk | Klmf | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Cqyqglq | Rddyp | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Gqrsyfp | Lkwc | $13B |
United States